All kidney transplant recipients require immunosuppression, the net level of which is difficult to assess. Current practice in assessing immune reactivity is to monitor levels of some immunosuppressive drugs. QuantiFERON Monitor® (QFM) is an in vitro diagnostic test that detects interferon-γ (IFN-γ) release in peripheral blood. Its clinical utility in assessment of the net state of immunosuppression in kidney transplant recipients has not been well studied. The aim of our study is to evaluate the discriminating value of QFM testing results for infection and rejection in a single-centre cohort of kidney transplant recipients.
Study Type
OBSERVATIONAL
Enrollment
150
Clinical Hospital Merkur
Zagreb, HR, Croatia
Infection
Interferon gamma level in patients with infection
Time frame: throughout the study period (Kidney transplant recipients from 1 day date of tx to 15 years after tx)
Rejection
Interferon gamma levels in patients with rejection
Time frame: throughout the study period (Kidney transplant recipients from 1 day date of tx to 15 years after tx)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.